β-リン酸三カルシウムを組み込んだ生分解性ゼラチンスポンジを用いた組換えヒト線維芽細胞増殖因子-2を用いた隆起増大術：犬を対象とした前臨床試験

Ridge augmentation using recombinant human fibroblast growth factor-2 with biodegradable gelatin sponges incorporating β-tricalcium phosphate: a preclinical study in dogs.

• S Hoshi
• T Akizuki
• T Matsuura
• T Ikawa
• A Kinoshita
• S Oda
• Y Tabata
• M Matsui
• Y Izumi

抄録

背景と目的:

線維芽細胞増殖因子-2(FGF-2)は、骨形成細胞の増殖と分化を制御し、結果として骨形成を促進する。β-三カルシウムリン酸塩（β-TCP）を組み込んだ生分解性ゼラチンスポンジは、成長因子の放出を制御し、十分な機械的強度と間葉系細胞の効率的な遊走を可能にする足場として報告されています。本研究では、組換えヒトFGF-2（rhFGF-2）とゼラチン/β-TCPスポンジの併用による犬の隆起増大効果を評価した。

BACKGROUND AND OBJECTIVE: Fibroblast growth factor-2 (FGF-2) regulates the proliferation and differentiation of osteogenic cells, resulting in the promotion of bone formation. Biodegradable gelatin sponges incorporating β-tricalcium phosphate (β-TCP) have been reported as a scaffold, which has the ability to control growth factor release, offering sufficient mechanical strength and efficient migration of mesenchymal cells. In this study, we evaluated the effects of the combined use of recombinant human FGF-2 (rhFGF-2) and gelatin/β-TCP sponge on ridge augmentation in dogs.

材料および方法:

この研究では、6頭の雄のビーグル犬を使用した。抜歯後12wk後、上顎犬歯の中歯側から3mm間隔で両側10×5mm(幅×奥行き)の鞍型の欠損部を作成した。実験部位では、0.3%rhFGF-2を浸潤させたゼラチン/β-TCPスポンジで欠損部を埋め、対照部位には生理食塩水を浸潤させたゼラチン/β-TCPスポンジを適用した。術後8週間後に定性・定量分析を行った。

MATERIAL AND METHODS: Six male beagle dogs were used in this study. Twelve wk after tooth extraction, bilateral 10 × 5 mm (width × depth) saddle-type defects were created 3 mm apart from the mesial side of the maxillary canine. At the experimental sites, the defects were filled with gelatin/β-TCP sponge infiltrated with 0.3% rhFGF-2, whereas gelatin/β-TCP sponge infiltrated with saline was applied to the control sites. Eight wk after surgery, qualitative and quantitative analyses were performed.

結果:

手術後8週目には、臨床的炎症の徴候は見られなかった。組織測定により、実験部位の新しい骨の高さ(2.98 ± 0.65 mm)は、対照部位(1.56 ± 0.66 mm; p = 0.004)よりも有意に大きいことが明らかになった。総組織高さは、統計的に有意な差は認められなかったが、実験部位（6.62±0.66mm）は対照部位（5.95±0.74mm）よりも大きかった（p = 0.051）。鋳造モデルの測定により，実験部位の残留欠陥高さ（2.31 ± 0.50 mm）は，対照部位の残留欠陥高さ（3.51 ± 0.78 mm；p = 0.012）よりも有意に小さいことが明らかになった．

RESULTS: There were no signs of clinical inflammation at 8 wk after surgery. Histometric measurements revealed that new bone height at the experimental sites (2.98 ± 0.65 mm) was significantly greater than that at the control sites (1.56 ± 0.66 mm; p = 0.004). The total tissue height was greater at the experimental sites (6.62 ± 0.66 mm) than that at the control sites (5.95 ± 0.74 mm), although there was no statistical significant difference (p = 0.051). Cast model measurements revealed that the residual defect height at the experimental sites (2.31 ± 0.50 mm) was significantly smaller than that at the control sites (3.51 ± 0.78 mm; p = 0.012).

結論:

rhFGF-2とゼラチン/β-TCPスポンジの併用は、イヌ鞍型骨欠損部の隆起増大を促進する。

CONCLUSION: The combined use of rhFGF-2 and gelatin/β-TCP sponge promotes ridge augmentation in canine saddle-type bone defects.

© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.